Logo 1 Logo 2

Clinical Trial Details

Trial ID: L7216
Source ID: NCT02730377
Associated Drug: Liraglutide
Title: Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Acronym: LIRA-PRIME
Status: COMPLETED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT02730377/results
Conditions: Diabetes|Diabetes Mellitus, Type 2
Interventions: DRUG: liraglutide|DRUG: alpha-glucosidase inhibitors|DRUG: DPP-4 inhibitors|DRUG: meglitinides|DRUG: SGLT-2 inhibitors|DRUG: sulphonylurea|DRUG: thiazolidinediones
Outcome Measures: Primary: Time to Inadequate Glycaemic Control, Inadequate glycaemic control was defined as glycosylated haemoglobin (HbA1c) of 7.0% (53 mmol/mol) or greater at two consecutive visits after the first 26 weeks of treatment and up to 104 weeks. 25%, median (50%) and 75% percentiles for the cumulative distribution function, are obtained from the Kaplan-Meier survival function. HbA1c was recorded at weeks 38, 52, 65, 78, 91 and 104., Weeks 26-104 | Secondary: Time to Premature Treatment Discontinuation (for Any Reason Including Inadequate Glycaemic Control), The time to premature treatment discontinuation (for any reason including inadequate glycaemic control) was analysed and presented using the generalised log rank test. 25%, median (50%) and 75% percentiles for the cumulative distribution function, are obtained from the Kaplan-Meier survival function., Weeks 0-104|Change in HbA1c, Change from baseline (week 0) in HbA1c at week 104 or at premature treatment discontinuation is presented., Week 0, week 104/premature treatment discontinuation|Participants Who Achieve HbA1c ≤6.5% (Yes/No), Participants who achieved HbA1c ≤6.5% (yes/no) is presented., Week 104/Premature treatment discontinuation|Participants Who Achieve HbA1c ≤7.0% Without Weight Gain, Participants who achieved HbA1c ≤7.0% without weight gain (yes/no) is presented., Week 104/Premature treatment discontinuation|Participants Who Achieve HbA1c ≤7.0% Without Treatment Emergent Severe Hypoglycaemic Episodes or BG Confirmed Symptomatic Hypoglycaemic Episodes, Severe or blood glucose (BG) confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \<3.1 millimoles per liter (mmol/L) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than the day after the last day on trial product. Participants who achieved HbA1c ≤7.0% without treatment emergent severe hypoglycaemic episodes or BG confirmed symptomatic hypoglycaemic episodes (yes/no) is presented., Week 104/Premature treatment discontinuation|Participants Who Achieve HbA1c ≤7.0% Without Weight Gain and no Treatment Emergent Severe Hypoglycaemic Episodes or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes, Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than the day after the last day on trial product. Participants who achieved HbA1c ≤7.0% without weight gain and no treatment emergent severe hypoglycaemic episodes or BG confirmed symptomatic hypoglycaemic episodes (yes/no) is presented., Week 104/Premature treatment discontinuation|Change in Fasting Plasma Glucose (FPG), Change from baseline (week 0) in FPG at week 104 or at premature treatment discontinuation is presented., Week 0, week 104/premature treatment discontinuation|Change in Body Weight, Change from baseline (week 0) in body weight at week 104 or at premature treatment discontinuation is presented., Week 0, week 104/premature treatment discontinuation|Change in Body Mass Index (BMI), Change from baseline (week 0) in BMI at week 104 or at premature treatment discontinuation is presented., Week 0, week 104/premature treatment discontinuation|Change in Blood Pressure (Systolic and Diastolic Blood Pressure), Change from baseline (week 0) in systolic and diastolic blood pressure at week 104 or at premature treatment discontinuation is presented., Week 0, week 104/premature treatment discontinuation|Number of Severe Hypoglycaemic Episodes, Severe hypoglycaemic episodes were defined as episodes that required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Number of severe hypoglycaemic episodes that occured during weeks 0-104 are presented., Weeks 0-104|Number of Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes, Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Number of severe or BG confirmed symptomatic hypoglycaemic episodes that occured during weeks 0-104 are presented., Weeks 0-104|Number of Documented Symptomatic Hypoglycaemic Episodes (ADA), Documented symptomatic hypoglycaemic were defined as episodes with typical symptoms of hypoglycaemia accompanied by measure plasma glucose concentration \<= 3.9 mmol/L. Number of documented symptomatic hypoglycaemic episodes that occured during the weeks 0-104 are presented., Weeks 0-104|Number of Serious Adverse Events (SAEs), A serious adverse event (SAE) was defined as any event that resulted in any of the following: death, life-threatening experience, in-patient hospitalisation or prolongation of existing hospitalisation, persistent or significant disability or incapacity, congenital anomaly or birth defect or suspicion of transmission of infectious agents via the trial product. An SAE was considered as treatment emergent if it had an onset or increase in severity on or after the time of first trial product administration and no later than 7 days after the time of last trial product administration. Number of treatment emergent serious adverse events are presented., Weeks 0-105|Number of AEs Leading to Permanent Discontinuation of Trial Product, An adverse event (AE) was any untoward medical occurrence in a participant who administered a product, and which did not necessarily had a causal relationship with this treatment. An AE was considered as treatment emergent if it had an onset or increase in severity on or after the time of first trial product administration and no later than 7 days after the time of last trial product administration. Number of treatment emergent AEs that led to permanent discontinuation of trial product are presented., Weeks 0-105|Change in Lipids: HDL Cholesterol, LDL-cholesterol, Total Cholesterol, Triglycerides, Change from baseline (week 0) in high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, total cholesterol (TC) and triglycerides (TG) at week 104 or at premature treatment discontinuation is presented., Week 0, week 104/premature treatment discontinuation|Change in Biochemistry- Alanine Aminotransferase (ALAT), Amylase, Aspartate Aminotransferase (ASAT), Lipase, Change from baseline (week 0) in alanine aminotransferase (ALAT), amylase, aspartate aminotransferase (ASAT) and lipase at week 104 or at premature treatment discontinuation is presented., Week 0, week 104/premature treatment discontinuation|Change in Biochemistry- Creatinine, Total Bilirubin, Change from baseline (week 0) in creatinine and total bilirubin (TB) at week 104 or at premature treatment discontinuation is presented., Week 0, week 104/premature treatment discontinuation|Change in Biochemistry- Estimated Glomerular Filtration Rate (eGFR) Serum, The estimated GFR was derived from serum creatinine using the MDRD (Modification of diet in renal disease) formula. eGFR was measured as milliliter per min per specific surface area (mL/min/SSA)., Week 0, week 104/premature treatment discontinuation|Change in Potassium, Change from baseline (week 0) in potassium at week 104 or at premature treatment discontinuation is presented., Week 0, week 104/premature treatment discontinuation|Change in Haemoglobin, Change from baseline (week 0) in haemoglobin at week 104 or at premature treatment discontinuation is presented., Week 0, week 104/premature treatment discontinuation|Change in Pulse, Change from baseline (week 0) in pulse at week 104 or at premature treatment discontinuation is presented., Week 0, week 104/premature treatment discontinuation
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 1991
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2016-03-28
Completion Date: 2019-08-12
Results First Posted: 2020-07-07
Last Update Posted: 2020-07-07
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama, 35211, United States|Novo Nordisk Investigational Site, Haleyville, Alabama, 35565-1719, United States|Novo Nordisk Investigational Site, Tuscumbia, Alabama, 35674, United States|Novo Nordisk Investigational Site, Fountain Hills, Arizona, 85268, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, 85018, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, 85037, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, 85050, United States|Novo Nordisk Investigational Site, Tempe, Arizona, 85283, United States|Novo Nordisk Investigational Site, Tucson, Arizona, 85741, United States|Novo Nordisk Investigational Site, Harrisburg, Arkansas, 72432-1132, United States|Novo Nordisk Investigational Site, Little Rock, Arkansas, 72212, United States|Novo Nordisk Investigational Site, North Little Rock, Arkansas, 72117, United States|Novo Nordisk Investigational Site, Searcy, Arkansas, 72143, United States|Novo Nordisk Investigational Site, Alhambra, California, 91801, United States|Novo Nordisk Investigational Site, Buena Park, California, 90620, United States|Novo Nordisk Investigational Site, Carlsbad, California, 92008, United States|Novo Nordisk Investigational Site, Coronado, California, 92118, United States|Novo Nordisk Investigational Site, Costa Mesa, California, 92627, United States|Novo Nordisk Investigational Site, Elk Grove, California, 95758, United States|Novo Nordisk Investigational Site, Encinitas, California, 92024, United States|Novo Nordisk Investigational Site, Huntington Beach, California, 92646, United States|Novo Nordisk Investigational Site, La Mirada, California, 90638, United States|Novo Nordisk Investigational Site, Lancaster, California, 93534, United States|Novo Nordisk Investigational Site, Lomita, California, 90717, United States|Novo Nordisk Investigational Site, Montclair, California, 91763, United States|Novo Nordisk Investigational Site, Northridge, California, 91325, United States|Novo Nordisk Investigational Site, Oxnard, California, 93030, United States|Novo Nordisk Investigational Site, Rancho Cucamonga, California, 91730-3063, United States|Novo Nordisk Investigational Site, Riverside, California, 92506, United States|Novo Nordisk Investigational Site, San Diego, California, 92111, United States|Novo Nordisk Investigational Site, San Diego, California, 92120, United States|Novo Nordisk Investigational Site, San Ramon, California, 94582, United States|Novo Nordisk Investigational Site, Tustin, California, 92780, United States|Novo Nordisk Investigational Site, Westminster, California, 92683, United States|Novo Nordisk Investigational Site, Centennial, Colorado, 80012, United States|Novo Nordisk Investigational Site, Centennial, Colorado, 80112, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, 80906, United States|Novo Nordisk Investigational Site, Golden, Colorado, 80401, United States|Novo Nordisk Investigational Site, Monument, Colorado, 80132, United States|Novo Nordisk Investigational Site, Chiefland, Florida, 32626, United States|Novo Nordisk Investigational Site, Clearwater, Florida, 33756, United States|Novo Nordisk Investigational Site, Fort Lauderdale, Florida, 33316, United States|Novo Nordisk Investigational Site, Hollywood, Florida, 33024, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, 32205, United States|Novo Nordisk Investigational Site, Kissimmee, Florida, 34741, United States|Novo Nordisk Investigational Site, Miami, Florida, 33174, United States|Novo Nordisk Investigational Site, Miami, Florida, 33175, United States|Novo Nordisk Investigational Site, Ocala, Florida, 34470, United States|Novo Nordisk Investigational Site, Ocoee, Florida, 34761, United States|Novo Nordisk Investigational Site, Orlando, Florida, 32819, United States|Novo Nordisk Investigational Site, Ormond Beach, Florida, 32174-6302, United States|Novo Nordisk Investigational Site, Oviedo, Florida, 32765, United States|Novo Nordisk Investigational Site, Palm Harbor, Florida, 34684-3609, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, 33027, United States|Novo Nordisk Investigational Site, Saint Petersburg, Florida, 33713, United States|Novo Nordisk Investigational Site, Seminole, Florida, 33773, United States|Novo Nordisk Investigational Site, Bainbridge, Georgia, 39819, United States|Novo Nordisk Investigational Site, Conyers, Georgia, 30094-5965, United States|Novo Nordisk Investigational Site, Perry, Georgia, 31069, United States|Novo Nordisk Investigational Site, Statesboro, Georgia, 30461, United States|Novo Nordisk Investigational Site, Suwanee, Georgia, 30024, United States|Novo Nordisk Investigational Site, Woodstock, Georgia, 30189-4255, United States|Novo Nordisk Investigational Site, Meridian, Idaho, 83646, United States|Novo Nordisk Investigational Site, Aurora, Illinois, 60506, United States|Novo Nordisk Investigational Site, Chicago, Illinois, 60616, United States|Novo Nordisk Investigational Site, Gillespie, Illinois, 62033, United States|Novo Nordisk Investigational Site, Wauconda, Illinois, 60084, United States|Novo Nordisk Investigational Site, Avon, Indiana, 46123, United States|Novo Nordisk Investigational Site, Evansville, Indiana, 47714, United States|Novo Nordisk Investigational Site, Greenfield, Indiana, 46140, United States|Novo Nordisk Investigational Site, Muncie, Indiana, 47304, United States|Novo Nordisk Investigational Site, Newton, Kansas, 67114, United States|Novo Nordisk Investigational Site, Park City, Kansas, 67219, United States|Novo Nordisk Investigational Site, Wichita, Kansas, 67205, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, 40503, United States|Novo Nordisk Investigational Site, Natchitoches, Louisiana, 71457-5881, United States|Novo Nordisk Investigational Site, Shreveport, Louisiana, 71105, United States|Novo Nordisk Investigational Site, Sunset, Louisiana, 70584, United States|Novo Nordisk Investigational Site, Elkridge, Maryland, 21075-6437, United States|Novo Nordisk Investigational Site, Oxon Hill, Maryland, 20745, United States|Novo Nordisk Investigational Site, Buckley, Michigan, 49620, United States|Novo Nordisk Investigational Site, Rochester, Michigan, 48307, United States|Novo Nordisk Investigational Site, Sterling Heights, Michigan, 48310-3503, United States|Novo Nordisk Investigational Site, Troy, Michigan, 48098, United States|Novo Nordisk Investigational Site, Belzoni, Mississippi, 39038, United States|Novo Nordisk Investigational Site, Port Gibson, Mississippi, 39150, United States|Novo Nordisk Investigational Site, Butte, Montana, 59701, United States|Novo Nordisk Investigational Site, Missoula, Montana, 59808, United States|Novo Nordisk Investigational Site, Fremont, Nebraska, 68025, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, 68144, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, 89118, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, 87102, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, 87108, United States|Novo Nordisk Investigational Site, Brooklyn, New York, 11215, United States|Novo Nordisk Investigational Site, New Windsor, New York, 12533, United States|Novo Nordisk Investigational Site, North Massapequa, New York, 11758-1802, United States|Novo Nordisk Investigational Site, Westfield, New York, 14787, United States|Novo Nordisk Investigational Site, Asheboro, North Carolina, 27203, United States|Novo Nordisk Investigational Site, Burlington, North Carolina, 27215, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, 28210, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, 28277-6594, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, 28277, United States|Novo Nordisk Investigational Site, Elizabeth City, North Carolina, 27909, United States|Novo Nordisk Investigational Site, Garner, North Carolina, 27529, United States|Novo Nordisk Investigational Site, Mooresville, North Carolina, 28117, United States|Novo Nordisk Investigational Site, Morganton, North Carolina, 28655, United States|Novo Nordisk Investigational Site, Whiteville, North Carolina, 28472, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, 58104, United States|Novo Nordisk Investigational Site, Columbus, Ohio, 43213, United States|Novo Nordisk Investigational Site, Dayton, Ohio, 45406, United States|Novo Nordisk Investigational Site, Franklin, Ohio, 45005, United States|Novo Nordisk Investigational Site, Mason, Ohio, 45040-6815, United States|Novo Nordisk Investigational Site, Toledo, Ohio, 43623, United States|Novo Nordisk Investigational Site, Wadsworth, Ohio, 44281, United States|Novo Nordisk Investigational Site, Edmond, Oklahoma, 73034, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, 73112, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, 73162-4704, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, 15009, United States|Novo Nordisk Investigational Site, Fleetwood, Pennsylvania, 19522, United States|Novo Nordisk Investigational Site, Harleysville, Pennsylvania, 19438, United States|Novo Nordisk Investigational Site, Jersey Shore, Pennsylvania, 17740, United States|Novo Nordisk Investigational Site, Lansdale, Pennsylvania, 19446-1002, United States|Novo Nordisk Investigational Site, Levittown, Pennsylvania, 19056-2404, United States|Novo Nordisk Investigational Site, Levittown, Pennsylvania, 19056, United States|Novo Nordisk Investigational Site, McMurray, Pennsylvania, 15317, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, 19114, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, 15236, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, 15243, United States|Novo Nordisk Investigational Site, Smithfield, Pennsylvania, 15478, United States|Novo Nordisk Investigational Site, Uniontown, Pennsylvania, 15401, United States|Novo Nordisk Investigational Site, Providence, Rhode Island, 02908, United States|Novo Nordisk Investigational Site, Anderson, South Carolina, 29621, United States|Novo Nordisk Investigational Site, Columbia, South Carolina, 29223, United States|Novo Nordisk Investigational Site, Greer, South Carolina, 29651, United States|Novo Nordisk Investigational Site, Indian Land, South Carolina, 29707, United States|Novo Nordisk Investigational Site, Pelzer, South Carolina, 29669, United States|Novo Nordisk Investigational Site, Simpsonville, South Carolina, 29681, United States|Novo Nordisk Investigational Site, Rapid City, South Dakota, 57702, United States|Novo Nordisk Investigational Site, Athens, Tennessee, 37303, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, 37404, United States|Novo Nordisk Investigational Site, Humboldt, Tennessee, 38343, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, 37660, United States|Novo Nordisk Investigational Site, Tullahoma, Tennessee, 37388, United States|Novo Nordisk Investigational Site, Arlington, Texas, 76014-2010, United States|Novo Nordisk Investigational Site, Arlington, Texas, 76015, United States|Novo Nordisk Investigational Site, Carrollton, Texas, 75010, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, 78404, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, 78413, United States|Novo Nordisk Investigational Site, Dallas, Texas, 75251, United States|Novo Nordisk Investigational Site, Fort Worth, Texas, 76164, United States|Novo Nordisk Investigational Site, Georgetown, Texas, 78626, United States|Novo Nordisk Investigational Site, Gonzales, Texas, 78629, United States|Novo Nordisk Investigational Site, Houston, Texas, 77024, United States|Novo Nordisk Investigational Site, Houston, Texas, 77025-1669, United States|Novo Nordisk Investigational Site, Houston, Texas, 77061, United States|Novo Nordisk Investigational Site, Houston, Texas, 77074, United States|Novo Nordisk Investigational Site, Houston, Texas, 77079, United States|Novo Nordisk Investigational Site, Houston, Texas, 77081, United States|Novo Nordisk Investigational Site, Irving, Texas, 75061-2210, United States|Novo Nordisk Investigational Site, Kerrville, Texas, 78028, United States|Novo Nordisk Investigational Site, Killeen, Texas, 76543, United States|Novo Nordisk Investigational Site, Longview, Texas, 75605, United States|Novo Nordisk Investigational Site, Missouri City, Texas, 77459, United States|Novo Nordisk Investigational Site, New Braunfels, Texas, 78130, United States|Novo Nordisk Investigational Site, San Antonio, Texas, 78240, United States|Novo Nordisk Investigational Site, Splendora, Texas, 77372, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, 77478, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, 77479, United States|Novo Nordisk Investigational Site, Waco, Texas, 76710, United States|Novo Nordisk Investigational Site, Bountiful, Utah, 84010, United States|Novo Nordisk Investigational Site, Saint George, Utah, 84790, United States|Novo Nordisk Investigational Site, Danville, Virginia, 24541, United States|Novo Nordisk Investigational Site, Gloucester Courthouse, Virginia, 23061, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, 23510-2015, United States|Novo Nordisk Investigational Site, Richmond, Virginia, 23219, United States|Novo Nordisk Investigational Site, Virginia Beach, Virginia, 23454, United States|Novo Nordisk Investigational Site, Bellevue, Washington, 98004-4604, United States|Novo Nordisk Investigational Site, Spokane, Washington, 99216-1557, United States|Novo Nordisk Investigational Site, Walla Walla, Washington, 99362-4445, United States|Novo Nordisk Investigational Site, Surrey, British Columbia, V3Z 2N6, Canada|Novo Nordisk Investigational Site, Mount Pearl, Newfoundland and Labrador, A1N 1W7, Canada|Novo Nordisk Investigational Site, Truro, Nova Scotia, B2N 1L2, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, L8M 1K7, Canada|Novo Nordisk Investigational Site, Sarnia, Ontario, N7T 4X3, Canada|Novo Nordisk Investigational Site, Strathroy, Ontario, N7G 1Y7, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, M3J 1N2, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, M9V 4B4, Canada|Novo Nordisk Investigational Site, Waterloo, Ontario, N2J 1C4, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, H4N 2W2, Canada|Novo Nordisk Investigational Site, St-Marc-des-Carrières, Quebec, G0A 4B0, Canada|Novo Nordisk Investigational Site, Quebec, G1G 3Y8, Canada|Novo Nordisk Investigational Site, Bogota, 110221, Colombia|Novo Nordisk Investigational Site, Bogota, 111211, Colombia|Novo Nordisk Investigational Site, Medellin, Colombia|Novo Nordisk Investigational Site, Bangalore, Karnataka, 560 017, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, 560002, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, 560054, India|Novo Nordisk Investigational Site, Mysore, Karnataka, 570001, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, 452008, India|Novo Nordisk Investigational Site, Nagpur, Maharashtra, 440003, India|Novo Nordisk Investigational Site, Pune, Maharashtra, 411001, India|Novo Nordisk Investigational Site, Pune, Maharashtra, 411004, India|Novo Nordisk Investigational Site, Pune, Maharashtra, 411013, India|Novo Nordisk Investigational Site, Hyderabad, Telengana, 500033, India|Novo Nordisk Investigational Site, Lucknow, Uttar Pradesh, 226005, India|Novo Nordisk Investigational Site, Noida, Uttar Pradesh, 201301, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, 700027, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, 700054, India|Novo Nordisk Investigational Site, Hubli, 580022, India|Novo Nordisk Investigational Site, Ludhiana, 141001, India|Novo Nordisk Investigational Site, Riga, LV1011, Latvia|Novo Nordisk Investigational Site, Riga, LV1057, Latvia|Novo Nordisk Investigational Site, Tukums, LV3101, Latvia|Novo Nordisk Investigational Site, Achrafieh, Lebanon|Novo Nordisk Investigational Site, Beirut, Lebanon|Novo Nordisk Investigational Site, Hazmieh, Lebanon|Novo Nordisk Investigational Site, Jbeil, Lebanon|Novo Nordisk Investigational Site, Toa Baja, 00949, Puerto Rico|Novo Nordisk Investigational Site, Trujillo Alto, 00976, Puerto Rico|Novo Nordisk Investigational Site, Dzerzhinskiy, 140091, Russian Federation|Novo Nordisk Investigational Site, Moscow, 101990, Russian Federation|Novo Nordisk Investigational Site, Moscow, 121293, Russian Federation|Novo Nordisk Investigational Site, Moscow, 125315, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, 197762, Russian Federation|Novo Nordisk Investigational Site, Belgrade, 11000, Serbia|Novo Nordisk Investigational Site, Kragujevac, 34000, Serbia|Novo Nordisk Investigational Site, Nis, 18000, Serbia|Novo Nordisk Investigational Site, Novi Sad, 21000, Serbia|Novo Nordisk Investigational Site, Adapazari, 54290, Turkey|Novo Nordisk Investigational Site, Istanbul, 34130, Turkey|Novo Nordisk Investigational Site, Istanbul, 34722, Turkey|Novo Nordisk Investigational Site, Istanbul, 34890, Turkey
URL: https://clinicaltrials.gov/show/NCT02730377

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress